Chimeric Therapeutics (ASX:CHM) Interest Received : A$0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Chimeric Therapeutics Interest Received?

Chimeric Therapeutics's Interest Received for the six months ended in Dec. 2023 was A$0.00 Mil.

Chimeric Therapeutics's Interest Received for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00 Mil.

Chimeric Therapeutics Interest Received Historical Data

The historical data trend for Chimeric Therapeutics's Interest Received can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimeric Therapeutics Interest Received Chart

Chimeric Therapeutics Annual Data

Trend

Jun21

Jun22

Jun23

Interest Received

0.03

Chimeric Therapeutics Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Interest Received	Get a 7-Day Free Trial			-	-	-	-	-

Chimeric Therapeutics Interest Received Calculation

A company's cash flow from operations for a time period can be determined using either the direct or indirect method. The indirect method modifies the operating section from accrual accounting to a cash basis by taking the net income generated in a period and adding or subtracting changes in the asset and liability accounts to determine the implied cash flow. However, the direct method uses actual cash inflows and outflows from the company's operations directly. Interest Received represents interest received by the company in the direct cash flow method.

Interest Received for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

Chimeric Therapeutics Interest Received Related Terms

Thank you for viewing the detailed overview of Chimeric Therapeutics's Interest Received provided by GuruFocus.com. Please click on the following links to see related term pages.

Chimeric Therapeutics (ASX:CHM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimeric Therapeutics Ltd (ASX:CHM) » Definitions » Interest Received

Comparable Companies

Traded in Other Exchanges

CHMMF:USA

Address

62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053

Website

https://www.chimerictherapeutics.com

Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.

Chimeric Therapeutics (ASX:CHM) Headlines

No Headlines